Together Against IBD
Two Teams, One Vision, Multiple Drug Candidate Therapies
We’re committed to beating inflammatory disease, and our complementary strengths make us far more capable of doing so.
Through our research and development efforts, we will relentlessly pursue novel therapies that break through the efficacy ceiling as we strive to improve the lives of patients living with IBD.
Gilead, Galapagos, and Inflammation
Gilead Sciences founded
Gilead research efforts expand to evaluate spleen tyrosine kinase inhibition and explore treatments for inflammatory diseases
Galapagos makes decision to focus on the development and execution of molecules in inflammation
Gilead and ONO partner to evaluate Bruton’s tyrosine kinase inhibitors for B-cell malignancies and inflammatory diseases
Gilead and Galapagos announce global collaboration to address inflammatory diseases
Gilead initiates Phase 3 studies of a Janus kinase 1 (JAK1) inhibitor for patients with rheumatoid arthritis, Crohn’s disease, and ulcerative colitis
Gilead initiates multiple Phase 2 studies of JAK1 pathway inhibition in additional inflammatory diseases
Gilead and Galapagos embark on a 10-year collaboration to discover and develop transformative therapies in inflammatory diseases
Gilead enters the microbiome space with Second Genome to identify biomarkers and potential new targets and drug candidates in IBD
Between us we have over 50 active trials investigating 11 separate potential therapies across multiple inflammatory disorders in various preclinical and clinical stages. These include one novel molecule currently in review by global regulatory agencies.
We’re also advancing IBD research. Gilead is working together with the Crohn’s and Colitis Foundation (CCF). As a member of IBD Plexus®, the CCF’s research information exchange platform, Gilead is contributing to the analysis of high-definition, multi-omic data using biosamples collected from patients with IBD.
And we’re just getting started.
GILEAD AND GALAPAGOS: FINDING ANSWERS TOGETHER.
Maximising our resources and collective thinking, we problem-solve across our global offices. And we’re not alone. We collaborate with external partners to develop innovative therapeutic approaches.